Attending Provider:					Ordering Provider:		IIIIIIIII BASSETT HE	ALTHCARE NETWORK
Please Cricle requests beddy  Check box for \$17 Till unless a  Indicated, tasts are considered  Routine.	e of Reques	st	Visit Number	•	Attending Provider:			
SPECIMEN   TABLE   CONTINUED   CONTINUED   TABLE   CONTINUED   CONTINUED   TABLE   CONTINUED	hart #: Location:				<ul><li>Check box for STAT.</li></ul>	Unless		REQUEST FORM #3 4878 (f:\lab\.doc)
STATE   Code   Test Name   STAT   La821075   Antegrature (State State	ient Name						7/19/2010,1/3/11,4/4/11,1/16/12,4/9/12	2, 7/1/13, 1/6/14, 7/7/14, 10/6/14, 5/14/15,8/4
WIDERS: Compliance is mandationy and regulated. For the laboratory to bill properly and receive payment, you must provide the specific Diagnosis Codes for each anaptation of the Additionals, only lests this are medically necessary for the indicated diagnosis of treatment should be ordered, with supporting documentation in the medical record. Under Additionals, only lests this are medically necessary for the indicated diagnosis of treatment should be ordered, with supporting documentation in the medical record. Under medication for that lest payment implies deviced, in these cases Medicare requires an Advance Beneficiary Notice (winter of liability) be signed to allow the hospital is bill the medicated for the things of things of the things of the things of the t	e of Birth						COLLECTED BY:	
WINDERSEAN   Compliance is mandation; and regulated. For the bibliocation; but bill properly and mobile properties, you must provide the appetite projects for each substantial work Additionally, which will be preceded by an '1 are ordered, and the diagnosis is not listed in the Local Coverage mandation in the moderal included diagnosis is not listed in the Local Coverage bettermination or National Coverage members for that Local providers will be preceded by an '1 are ordered, and the diagnosis is not listed in the Local Coverage bettermination or National Coverage members for that Locality to the providers of the moderal providers of t	iagnosis Code: escriptive Diagn	nosis:						
BIOOD BANK TESTS   Code	OVIDERS: Co ered. Addition ent Medicare in erminations fo	ompliance is manda ally, only tests that regulations, when our that test, payment	are medically ned certain laboratory t t may be denied. I	cessary for the inditests (indicated by In these cases Me	cated diagnosis or treatment an *) are ordered, and the dicare requires an Advance	nt should be ordered, v diagnosis is not listed	vith supporting documentati in the Local Coverage Deter	on in the medical record. Under mination or National Coverage
Code	atient has	signed ABN V	Vaiver (ABN)	☐ Patie	nt refused to sign AE	SN Waiver (ABNR	) 🛘 ABN not requir	ed
LAB288   Separate and Hold	BLOOD	BANK TESTS				RHOGAM ORDERS		
LAB21083 Cord Blood Holds*  LAB276 Type and Screen 1				;		Code	Test Name	STAT
LAB278   Type and Screen		•				LAB21075		
LAB2107   Direct Antiglobulin Test 3						□ Mioro Doog (	` '	)
LAB21070   Obstetrical Antibody Titer   LAB21070   Obstetrical Antibody Titer   LAB21071   Infant Group and Rh   LAB21071   Infant Group and Rh   LAB21072   Infant Group and Rh   LAB21076   PostPartum Rhogam   Infant group and Rh results:   LAB21076   Antigen Typing   LAB21078   ABO/Rh Type Only   BAB078h Type Only   BAB078h Type Only   LAB21078   ABO/Rh Type Only   BAB078h Type On							12 weeks gestation of it	:88)
LA821070   Desterical Antibody Titer								: Location:
LAB21072 Antigen Typing		•				3		
LABB9S ABOURT Type Only    ITANISEUSION REACTION WORKUE	LAB2107		,			LAB21076 Po	stPartum Rhogam	
A Positive	•					Infant o	roup and Rh results:	
LAB893 Transfusion Reaction Workup	LAB895 ABO/Rh Type Only						•	
A Fetal Screen is included in a postpartum request for Rhogam. A Fetal Hornoglobin Stain will be performed for any Fetal Screen resulted as positive, invalid or when the baby is Weak D positive for the Rh(D) antigen, to determine the appropriate dose of Rhogam. A Fetal Hornoglobin Stain will be performed for any Fetal Screen resulted as positive, invalid or when the baby is Weak D positive for the Rh(D) antigen, to determine the appropriate dose of Rhogam.    Compose					_			
HLA YPING FOR PLATELET REQUESTS ONLY   LAB21073   HLA A, B Antigen Typing 4				ıp				
LAB21073 HLA A,B Antigen Typing 4 LAB21074 HLA Cytotoxic Antibody Screen 4    CROSSMATCH/ORDER OF BLOOD COMPONENTS   INSTRUCTIONS: Indicate the product that has been ordered by circling the appropriate code and indicating the # of units. RCP orders include a TSC (Type and Screen which includes a cold agglutinin screen) and XM (crossmatch), Indicate date, time and location of the planned transfusion for all products ordered. Circle an indication for use and any special requirements necessary for transfusion.  - STAT - URG Planned Transfusion/Surgery Date:			•					
LAB21074   HLA Cytotoxic Antibody Screen 4				TS ONLY				
CROSSMATCH/ORDER OF ELOOD COMPONENTS   INSTRUCTIONS: Indicate the product that has been ordered by circling the appropriate code and indicating the # of units. RCP orders include a TSC (Type and Screen) and XM (crossmatch). Indicate date, time and location of the planned transfusion for all products ordered. Circle an indication for use and any special requirements necessary for transfusion.					_			
Code   Component   # of Units   Code   Component   # of Units   Code   Component	Indicate transfusi	date, time and loo on.	cation of the plan	nned transfusion	for all products ordered.	Circle an indication	for use and any special r	
Products   Products   Products   Products   Products   Products								Component
Special Requirements:   1. Autologous   2. Directed   3. Eactor VIII (Recombinant)   2. Factor VIII (Recombinant)   2. Factor VIII (Recombinant)   3. Emerity (Recombinant)   4. Other:	_AB21077			LAB21079			LAB21080	
1. Active Bleed/Trauma 2. Hgb < 8 or Hct < 25 3. H/H > 8/25 with clinical risk factors 4. H/H > 8/25 ordered by an attending 5. Pre-op scheduled within 48 hours 6. Cardiac Surgery (use CRCP code) 7. Stay Ahead/ Number of Units  Code Component # of Units  Indication for use:  Ind	Special Requirements:  1. Autologous 2. Directed 3. CMV Negative 4. Irradiated 5. Split/Aliquot			1. CM 2. Irra 3. HL/ 4. Cro	al Requirements:  IV Negative diated A Matched assmatched		Type of Product  1. Factor VIIa (Novoseven)  2. Factor VIII (Recombinant)  3. Benefix-Factor IX (Recombinant)  4. Other:  Other information required:	
3. H/H > 8/25 with clinical risk factors 4. H/H > 8/25 ordered by an attending 5. Pre-op scheduled within 48 hours 6. Cardiac Surgery (use CRCP code) 7. Stay Ahead/ Number of Units  Code	1. Active Bleed/Trauma 1. Plat				elet Count <50,000.		Patient weight: (kgs)	
4. H/N > 8/25 ordered by an attending 5. Pre-op scheduled within 48 hours 6. Cardiac Surgery (use CRCP code) 7. Stay Ahead/ Number of Units  Code	3. H/H > 8/2	25 with clinical risk t						
S. No platelet count available.  S. No platelet count available.  Frequency of Dose:				4. Mas	ssive Transfusion		Dosage: International Units	
AB21081 Plasma Products				5. 110	piateiet courit available.		Frequency of Dose:	
Indication for use:  1. PT/PTT above normal range. 2. Reversal of anti-coagulant therapy. 3. Hematology MD consulted. 4. Invasive procedure. 5. No PT/PTT results available.  Indication for use:  1. Hemophilia A/Factor VIII 2. Hypofibrinogenemia 3. VonWillebrand's Disease  Provider's Signature:  Signed Date and Time:	Code	Component	# of Units	Code	Component	# of Units	TISSUE PRODUCT	
Indication for use:  1. PT/PTT above normal range. 2. Reversal of anti-coagulant therapy. 3. Hematology MD consulted. 4. Invasive procedure. 5. No PT/PTT results available.  Size/Volume: Quantity:  Provider's Signature: Signed Date and Time:	AB21081			LAB21082	Cryoprecipitate		Product·	
Indication for use:  1. PT/PTT above normal range. 2. Reversal of anti-coagulant therapy. 3. Hematology MD consulted. 4. Invasive procedure. 5. No PT/PTT results available.  Indication for use:  1. Hemophilia A/Factor VIII 2. Hypofibrinogenemia 3. VonWillebrand's Disease  Provider's Signature:  Signed Date and Time:		Products						
1. PT/PTT above normal range. 2. Reversal of anti-coagulant therapy. 3. Hematology MD consulted. 4. Invasive procedure. 5. No PT/PTT results available.  Indication for use:  1. Hemophilia A/Factor VIII 2. Hypofibrinogenemia 3. VonWillebrand's Disease  Provider's Signature:  Signed Date and Time:	Indication for use:							
2. Hypofibrinogenemia 3. VonWillebrand's Disease 4. Invasive procedure. 5. No PT/PTT results available. 2. Hypofibrinogenemia 3. VonWillebrand's Disease 3. VonWillebrand's Disease  Signed Date and Time:	1. PT/PTT	above normal rar					Quantity:	
4. Invasive procedure. 5. No PT/PTT results available. 3. VonWillebrand's Disease  Signed Date and Time:								
5. No PT/PTT results available.  Signed Date and Time:			u.			Provider's S	ignature:	
							_	
			ble.			Signed Date	and Time:	

## **REFLEXIVE TESTING**

- 1. When atypical antibodies are detected, antibody identification studies may be performed.
- When atypical antibodies are detected, antibody identification studies will be performed. If a
  nonspecific Cold Agglutinin has been identified, a Cold Agglutinin Titer and Thermal Amplitude
  Studies will be performed.
- 3. When DAT is positive due to IgG, eluate study may be performed (only if patient has been pregnant or transfused in past three months).
- 4. Testing performed by SUNY Upstate Medical University for HLA matched Platelet Requests only.
- 5. Infant group, RH and DAT will be performed on cord blood specimens collected on RH negative and Type O mothers.
- 6. A urine sediment examination is performed and billed when RTUA (LAB21012) is ordered and the sample is cloudy or an abnormality is detected.
- 7. For the Obstetrical Type and Screen received at time of delivery When atypical antibodies are detected, antibody identification studies will be performed and 4 red cell products will be crossmatched at a minimum with products negative for the corresponding antibody.
- 8. Testing performed by Albany Medical Center for Fetal Hemoglobin Stain (LAB762) only.